Ab­b­Vie’s Skyrizi helps more Crohn's pa­tients stay off steroids than J&J’s Ste­lara, PhI­II da­ta show

Ab­b­Vie’s Skyrizi has demon­strat­ed sig­nif­i­cant­ly high­er rates of steroid-free clin­i­cal and en­do­scop­ic re­mis­sion ver­sus ri­val John­son & John­son’s Ste­lara in a Phase III tri­al, help­ing set the Crohn’s dis­ease drug apart in an in­creas­ing­ly com­pet­i­tive mar­ket.

Ste­lara won an FDA ap­proval for Crohn’s dis­ease in 2016, while Skyrizi was ap­proved three years lat­er in 2019. But the com­pe­ti­tion is heat­ing up with Ste­lara biosim­i­lars set to en­ter the mar­ket in 2025, gov­ern­ment price ne­go­ti­a­tions in 2026, and a new ri­val emerg­ing in the form of Pfiz­er’s oral S1P in­hibitor Vel­sip­i­ty for ul­cer­a­tive col­i­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER